Free shipping on all orders over $ 500

Epigenetic Reader Domain Epigenetic Reader Domain

Cat.No.  Name Information
M7126 PF CBP1 PF CBP1 is a selective CBP/p300 bromodomain inhibitor.
M6118 666-15 666-15 is a potent and selective CREB inhibitor with an IC50 of 81 nM.
M2903 OTX015 (Birabresib) OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4.
M2190 I-BET-762 I-BET-762 (GSK525762) is a selective small molecule BET inhibitor.
M2167 (+)-JQ1 (+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.
M2096 GSK1210151A GSK1210151A (I-BET151) is an inhibitor of the BET family with IC50 of 0.5 μM, 0.25 μM and 0.79 μM for BRD2, BRD3 and BRD4, respectively.
M29389 ZL0590  ZL0590 is a potent, orally active BRD4 BD1-selective inhibitor with an IC50 of 90 nM for human BRD4 BD1. ZL0590 exhibits significant anti-inflammatory activities.
M25522 UMB298 UMB298 is a potent and selective CBP/P300 bromodomain inhibitor.
M25395 GSK1379725A GSK1379725A (AU1) is the first selective BPTF (Bromodomain PHD Finger Transcription Factor) ligand with a Kd of 2.8 uM, showing no binding activity for Brd4.
M25393 BPTF-IN-BZ1 BPTF-IN-BZ1 is a BPTF (Bromodomain PHD Finger Transcription Factor) inhibitor, with a high potency (Kd = 6.3 nM).
M21674 C-82 C-82 is a specific CBP/β-catenin antagonist. It inhibits the binding between β-catenin and CBP and increases the binding between β-catenin and p300.
M21109 Inobrodib Inobrodib (CCS1477, CBP-IN-1) is an orally active, potent and selective p300/CBP inhibitor. inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM and has a 170/130 fold selectivity compared to BRD4 with a Kd of 222 nM. Inobrodib (CCS1477) acts by inhibiting the expression and function of androgen receptor (AR) and by inhibiting c-Myc.
M21106 E7386 E7386 is an orally active and selective inhibitor of β-catenin/CBP protein interactions and is a key node in the long-studied Wnt/β-catenin cancer pathway.
M20613 PF-CBP1 HCl PF-CBP1 HCl is a highly selective inhibitor of the bromodomain of CREB-binding protein(CREBBP).It inhibits CREBBP and p300 bromodomains with IC50 of 125 and 363 nM respectively.
M13819 BMS-986158 BMS-986158 is a potent BET inhibitor with IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.
M13818 BAY-850 BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM.
M13817 (R)-(-)-JQ1 Enantiomer (R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.
M13435 CFT8634 CFT8634 is an inhibitor of BRD9 for the study of brD9-dependent cancers, including synoviosarcomas and smarCB1-deficient cancers.
M13430 Ziftomenib Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity.
M13387 Revumenib (SNDX-5613) Revumenib (SNDX-5613) is a first-in-class, effective and selective Menin-MLL binding inhibitor with Ki of 0.15 nM. Revumenib (SNDX-5613) can be used to study MLL gene rearrangement in acute leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.